Hepatitis C virus Non-enveloped capsid-like particle (HCVne) ERK5 mef2 Cell signaling Hepatitis C virus (HCV) is an RNA positive strand virus, member of the Flaviviridae family. The viral particle is composed of a capsid containing the genome, surrounded by E1 and E2 proteins, however different forms of viral particles have been observed including non-enveloped particles. Previous reports have proposed that hepatitis C non-enveloped capsid-like particles (HCVne) enter cells of hepatic origin via clathrin-mediated endocytosis, during which different signaling events occur. In this report we show that HCVne particles are capable of inducing the recently discovered ERK5 pathway, in a dose dependent way. The ERK5 pathway can be activated by growth factors and other extracellular signals. This specific activation occurs through a well characterized upstream kinase, MEK5, and is capable of inducing gene regulation of mef2. In contrast, when HCV core structural and NS5A non-structural proteins were expressed endogenously no activation of this pathway was detected. These cell signaling events could be of critical importance and might give clues for the elucidation of cellular manifestations associated with HCV infection.
Introduction
An estimated 3% of the world's population is infected by hepatitis C (HCV), an enveloped positive-strand RNA virus, with a genome of approximately 9600 nucleotides, encoding structural (Core, E1, E2), p7 and six non-structural (NS2, NS3, NS4A, NS4B, NS5A, NS5B) proteins [1] [2] [3] . In most infected individuals, this virus evades the immune system and establishes a chronic infection that can lead to cirrhosis, liver cancer and death [4, 5] . The HCV virion nucleocapsid is surrounded by a lipid layer containing glycoproteins E1 and E2 [1] [2] [3] . However, different forms of HCV particles are present in the circulation of infected individuals, among them are naked capsids [6] [7] [8] , capable of entering cells and causing signaling events [9] [10] [11] . In this study we investigate the interplay of the HCV core and NS5A proteins as well as non-enveloped capsid-like particles (HCVne) with the MAPK (mitogen-activated protein kinases)-ERK5 pathway. ERK5 (extracellular signal-regulated protein kinase 5), also known as BMK1 (Big Mitogen Kinase 1), is a MAPK showing 80% similarity with ERK 1/2 proteins [12] . This kinase contains the typical ERK phosphorylation motif (TEY) and a unique C-terminal region believed to be responsible for its distinct biological activities [13] . Its activity is increased in response to growth factors, oxidative stress and hyperosmolarity, via a direct phosphorylation by MEK5 [14] . It is important to note that ERK5 has been implicated in different types of cancers as well as in angiogenesis, probably due to the proven activation of the Ras/Raf pathway [15, 16] . Until now no information about the involvement of this pathway in HCV infection has been reported. Data in this study suggested that the MEK5-ERK5 pathway can be activated by HCVne but not by endogenously expressed core or NS5A proteins. Furthermore, we provide evidence that this pathway can induce MEF2 activation, a well known downstream target of the pathway.
Materials and methods

Plasmids
The HCV genotype 1a (H) [17] was used to generate the plasmid constructs of this study. Core sequence was digested out as an NdeI fragment from plasmid pHPI 1327 [11] and inserted into the SmaI site of pCI plasmid (Promega) generating plasmid pHPI 1430. Plasmid pHPI 1404 producing NS5A protein has been described previously [18] . Plasmids pHPI 1319 [11] (full-length core C 191 ), pHPI 1558 (P. Tsitoura unpublished) (truncated core form C 179 ), and plasmid pET-9d-GFP [19] were used for production of soluble proteins. For the construction of a baculovirus expressing core protein under a CMV promoter, an NdeI fragment from pHPI 1327 plasmid was introduced to StuI-digested pRB5850 plasmid, kindly provided by Dr. B. Roizman yielding pHPI 1488. For construction of NS5A expressing baculovirus, plasmid pHPI 8119 was kindly provided by Dr. A. Kakkanas (unpublished data). MEF2A-LUC was a gift from Dr. S. Khochbin [20] . MEK5WT, MEK5AA and MEK5DD were from Dr. J.D. Lee [21] . Plasmid pCI ERK5 FL was a gift from Dr. A. Winoto [16] . The pSiren ERK5 was a gift from Dr. M.Villalba [66] and GFP-Rab5WT and GFP-Rab5S34N were a gift from Dr. Juan S. Bonifacino [22] .
Cells and reagents
HepG2 (human hepatocellular liver carcinoma cell line) and Spodoptera frugiperda Sf9 cells were purchased from ATCC. Huh-7 (human hepatoma) cells were kindly provided by Dr. R. Bartenschlager (University of Heidelberg, Germany). The following antibodies were used: rabbit anti-ERK5 (Sigma), rabbit anti-phospho-p44/42 (Cell Signaling), rabbit anti-ERK1 (Santa Cruz), mouse anti-EE autoantigen 1 (EEA1) (BD Biosciences), mouse anti-actin (Chemicon), rabbit and mouse Alexa −488, −546 (Molecular Probes), rabbit anti-core [11] , and rabbit anti-NS5A [23] . Protein-A agarose was from Santa Cruz, recombinant human EGF from R&D, and inhibitors UO126-PD98059 from Cell Signaling.
Cell culture, transient transfection and Western blotting
Cells were grown in Dulbecco Modified Eagle Medium (DMEM) containing a low glucose concentration (1000 mg/l) and antibiotics (penicillin at 100 U/ml, streptomycin at 100 μg/ml) and supplemented with 10% Fetal Calf Serum (FCS). Transient transfection of expression plasmids was performed with JetPEI reagent (PolyPlus) according to the manufacturer's protocol. Cells were lysed in ice-cold lysis buffer [1% Triton X-100, 50 mM KCl, 10 mM Tris pH 7.5, 1 mM DTT, 2 mM MgCl 2, complete-mini protease inhibitor cocktail tablets (Roche), 1 mM PMSF, 2 mM sodium orthovanadate], electrophoretically separated on 6, 8 or 10% SDS-gels, transferred onto nitrocellulose membranes, incubated with appropriate antibodies and detected by enhanced chemiluminescence (Pierce). Quantity One 4.4.1 software (Bio-Rad) was used for gel band quantification. Immunoprecipitation was performed as previously described [18] . For co-immunoprecipitation, lysates from HepG2 transfected cells (0.5 ug plasmid DNA/well) were further diluted fivefold in RIPA buffer (50 mM Tris-cl pH 7.4, 150 mM NaCl, 1% NP40, 0.25% Na-deoxycholate, 1 mM PMSF, 1× Roche complete mini protease inhibitor cocktail, 1× Roche PhosSTOP Phosphatase Inhibitor cocktail) and incubated on a rotary shaker at 4°C overnight, with antibody against ERK5 (Sigma). Resulting complexes were precipitated with protein A-agarose beads (Santa Cruz), followed by three washes with lysis buffer, separated on 8% SDS-polyacrylamide, transferred onto nitrocellulose membranes and finally blotted with ERK5 antibody. For luciferase assays, HepG2 cells were transfected as previously described. Twenty-four hours post transfection cells were starved by incubation with DMEM without FCS for 8 to 12 h and then HCVne particles (corresponding to approximately 5 ng of core protein) were added for 18 h. A similar protocol was followed for the controls. Cell extracts were prepared and luciferase assays were performed using the Luciferase Assay System (Promega) according to the manufacturer's instructions. The reaction was performed and measured in a luminometer GloMax™ 20/20 (Promega). The protein concentration was determined with a protein assay kit (Bio-Rad) and used for normalization of the luciferase assays. All experiments were repeated at least eight times in duplicates or triplicates including all necessary controls, and results were analyzed using the Student t-test. The level of significance was set as P b 0. 05 (*), P b 0. 01 (**), P b 0.001 (***).
Baculovirus expression system
The S. frugiperda Sf9 cell line was used for the generation and propagation of the recombinant baculoviruses Bac1488 and Bac8119 (P. Tsitoura and A. Kakkanas, unpublished data). Cells were maintained in Sf900II SFM (Gibco) medium supplemented with 5% fetal bovine serum at 27°C. Generation of recombinant baculoviruses was performed according to standard protocols using Baculogold linearized DNA (BD Biosciences) and propagation of viruses was performed in 5% Sf900II medium supplemented with 50 μg/ml gentamycin (Gibco) [11] . A control GFP virus (Bac 1746) was also produced [10] .
For baculovirus transduction of mammalian cells, HepG2 cells at a density of 5 × 10 5 were infected with an MOI of 50 for 3 h at room temperature. Following infection, 5 mM of sodium butyrate was added in the medium for 24 h. After 48 h of infection, cells were lysed as described previously.
Generation of cell lines expressing HCV core protein
HepG2 Tet-on stable cell lines (Clontech) expressing the core protein were generated as follows: cloning of the core (aa: 1-191) coding sequence from pHPI 1327 into the EcoRI site of pTRE expression vector (Clontech) yielded pHPI 1489. Plasmid pHPI 1489 was electrotransfected in HepG2 Tet-on cells that were grown in presence of 100 μg/ml G418. Transfected cells were selected by addition of 200 μg/ml hygromycin and individual clones were obtained by limited dilution. Induction in HepG2 Tet-on core cell lines was performed by addition of 10 ug/ml doxycycline for 24-48 h.
Production of HCV non enveloped capsids (HCVne) and soluble core protein
The capsid-like particles were isolated from cell lysates, as previously described [9] [10] [11] 24] . Briefly, fractions (650 μl each) were collected from the top of the sucrose gradient, the density was determined by refractometry. HCV core antigen in collected fractions [11] and cell lysates expressing core protein was estimated both with the Ortho HCV core antigen ELISA test system (Ortho-Clinical Diagnostics) using serial dilutions of a purified recombinant core protein as standard curve, and by densitometric analysis of band intensities from a single film obtained after SDS-PAGE followed by immunoblotting. Expression and purification of soluble proteins have already been described [11] .
Immunofluorescence staining
Following addition of HCVne, corresponding to 10 ng of core protein, at the indicated time cells grown on coverslips were washed three times with phosphate-buffered saline (PBS), fixed with 4% (w/ v) paraformaldehyde in PBS (30 min) and the remaining reactive groups were blocked with 100 mM glycine. Cells were permeabilized with 0.02% (v/v) Triton X-100, and incubated with the appropriate primary and secondary antibodies for 45 min respectively. Slides were examined using a Leica TCS-SP5 confocal microscope. Sequential scanning between channels was used to separate fluorescence emission from different fluorochromes and to completely eliminate bleed-through between channels. Typically, nine to fifteen confocal sections from three to five independent experiments, were quantified for co-localization of core and EEA1 puncta using the co-localization function in Image-Pro Plus software (Media Cybernetics). A similar approach has been used to quantify the co-localization of other proteins as described previously [9] .
Results
Potency of endogenously expressed HCV core and NS5A proteins to activate the ERK5 pathway
ERK5 is a member of MAPK that has been found in a phosphorylated state in cancers of different origins including liver cancer [12, 15, 16, 25] .
HCV is known to produce hepatocellular carcinoma at late stages of infection [4, 26] . Therefore, the ability of two HCV proteins, known to interact with different signaling pathways, was tested for ERK5 activation. Numerous antibodies exist that are purported to be specific for the phosphorylated ERK5 protein, however we have not found these reagents to react satisfactory under our experimental conditions. Thus, we have used the migrational shift seen on polyacrylamide gels of phosphorylated forms of proteins to determine whether phosphorylation has occurred. At the time this study was initiated, no positive control for ERK5 pathway in cells of hepatic origin existed, therefore epidermal growth factor (EGF), serum and insulin were tested and EGF was retained as positive control throughout this study (Fig. 1B) .
Transfections with plasmids expressing one structural, core, as well as one non-structural HCV protein, NS5A (Fig. 1A) , were performed and endogenous ERK5 expression was investigated. Based on our results, neither expression of core nor NS5A proteins when expressed were able to activate ERK5 ( Fig. 2A) . To further confirm the absence of band shifting, immunoprecipitation experiments with ERK5 antibody were developed by using cell lysates transfected with the same expression plasmids (core and NS5A) followed by immunodetection with the same antibody (Fig. 2C ). In addition, cell transduction with baculoviruses expressing core (Bac1488) or NS5A (Bac 8119) was performed (Fig. 2B) . Furthermore, an inducible HepG2 Tet-on cell line expressing core protein in the presence of doxycycline ( Fig. 2D ) was tested. In all these cases no ERK5 phosphorylation was observed, suggesting that these proteins even when intracellularly expressed at a high level, are not able to activate the pathway.
ERK5 pathway activation by HCVne particles
Previously published results suggested that HCV nucleocapsids without a lipid envelope circulate in the serum of HCV infected patients [6] [7] [8] 27] . As previously described [9] [10] [11] we were able to generate non-enveloped core capsids (HCVne) -using the baculovirus expression system producing structural core proteinthat are endocytosed in a clathrin-dependent way during which the ERK 1/2 pathway can be activated, thus producing immediate early genes activation [9] . To test if the ERK5 pathway can also be activated by these capsids, HepG2 cells were challenged with HCVne. A fivefold activation was observed after 30 min of incubation at 37°C (Fig. 3A) . Similar activation was also observed in Huh7 (Fig. 3B ) as well as in human brain cells SK-N-SH (data not shown) although a difference in the fold of activation was observed. As controls, we used either a fraction of the same sucrose density from infected Sf9 cells with Bac1746 -a control baculovirus expressing GFP [10] (Fig. 3C ) or heatdenatured HCVne particles (treated for 1 h at 100°C) (Fig. 3D) as well as 60% sucrose (data not shown). In all these cases no ERK5 activation was observed. Specificity of this phenomenon was further proved by investigating the correlation of increasing HCVne particles concentration with increasing ERK5 phosphorylation (Fig. 3E) . It is also important to mention that when soluble core protein, (1-191aa) or truncated (1-179aa), or GFP, all of bacterial origin were used exogenously in the same cells no ERK5 activation was observed (Fig. 3F) . The same result was observed when very high concentrations of bacterial core protein (1-191aa) were used (Fig. 3G) . This finding allowed us to insinuate that it is the particulate form of the capsid and not the protein per se that is responsible for this phenomenon.
ERK5 activation by HCVne particles probably occurs through MEK5
Up until now, in the absence of broadly accepted selective inhibitors of ERK5, the most commonly used inhibitors to block the ERK5 pathway are MEK1/2 inhibitors UO126 and PD98059 [28] , but with ambiguous and often cell type specific results. Their precise mechanism of action on MEK5 remains unknown.
We have observed an inhibition of ERK 1/2 activation but no effect on ERK5 phosphorylation (data not shown) by using different concentrations of these inhibitors at low concentrations. In contrast, at high concentrations (20 μΜ) and increased pre-treatment time (3 h), UO126 inhibitor was able to block the pathway after stimulation with EGF as well as after 30 min of incubation with HCVne (Fig. 4A ). Previous studies [9] have shown that HCVne particles entered cells in a clathrin and pH dependent endocytosis, "traveling" from early to late endosomes and finally reaching lysosomes. To eliminate the possibility that the loss of ERK5 signal was produced by decrease of binding and entry of HCVne particles, we investigated the capacity of these particles to enter Huh7 cells. Cells were pretreated with UO126 inhibitor (20 μΜ-3 h) and particles were added for 30 min at 37°C, prior to fixation and labeling for core and EEA1 (a specific endosomal marker) antigens. At this time point we have previously observed induced phosphorylation of ERK5 (Fig. 1B) and as already reported a number of uptaken HCVne were still present in early endosomes although the maximum co-localization was evaluated at 15 min postbinding/uptake [9] . Subsequently cells were visualized using confocal microscopy and fifteen confocal sections from three independent experiments were analyzed for colocalization with the specialized co-localization function of the Image-Pro Plus software. As shown in Fig. 4B e, f and g, no differences in rate of endocytosis rate between inhibitor treated and non-treated cells -both incubated with HCVnewere observed. It is interesting to note that even at very high concentrations the PD98059 inhibitor was not able to block ERK5 phosphorylation, although it blocked very efficiently the ERK 1/2 pathway activation (Fig. 4C) . The difference observed with these two inhibitors was probably due to the efficacy or mechanism of action of each agent. Minimal cell toxicity was observed in drug-treated cells through the spectra of concentration used in this experiment (data not shown).
Moreover, in HepG2 cells transfected with pSIREN shERK5 plasmid, a considerable silencing of ERK5 expression accompanied by reduced phosphorylation was observed compared to cells treated with the control vector, after incubation with HCVne for 30 min at 37°C (Fig. 4Da and d) indicating the specificity of the cell signaling phenomena observed. Additionally, in the same lysates the ERK1/2 expression was not affected (Fig. 4b, c and d) .
Taken together these data suggested that ERK5 activation by HCVne particles probably occurs through MEK5, although a possible alternative route affecting this kinase activation cannot be excluded.
ERK5 phosphorylation is followed by mef2 activation
Stimulation of MAPK pathway is followed by transcriptional promoter activation. The ERK5 pathway has been implicated in the activation of different genes, like c-fos, fra-1 and c-jun, although with conflicting results, probably due to tissue specificity [29, 30] . The most commonly activated promoter elements downstream of ERK5, in a great number of studies, is mef2 (myocyte enhancer factor-2) [31] [32] [33] [34] . Therefore, we used plasmid containing mef2A promoter elements fused to the coding sequences of luciferase gene. As shown in Fig. 5A , an important up-regulation of luciferase activity was observed with mef2A plasmid following incubation of the transfected cells with HCVne particles compared to the heat-denatured particles. Luciferase rates were measured as described before. As shown in Fig. 5B , the increase in mef2A luciferase levels due to HCVne particles is not observed when this MEK5 mutant was used, supporting the notion that mef2A activation is suggested to be MEK5 dependent.
MEK5-ERK5-mef2 modulation is HCVne endocytosis-dependent
As previously reported HCVne particles are clathrin-mediated endocytosed in cells of hepatic origin [9] . In order to understand if ERK5 up regulation was linked to endocytosis of HCVne, cells of hepatic origin were co-transfected with mef2A plasmid, MEK5WT or MEK5AA or MEK5DD (constitutively active) and either GFP-Rab5WT or GFP-Rab5S34N. Rab5S34N is a dominant negative GDP-binding mutant shown to reduce endocytosis of different ligands. The activity of mef2A-luc in cells co-expressing MEK5WT and Rab5WT was used as control. As demonstrated in Fig. 6A we observed that mef2a-luc activity was significantly reduced when MEK5WT was co-expressed with Rab5S34N, compared to the Rab5WT, indicating that this activation was sensitive to endocytosis of HCVne particles. This result was further confirmed by endogenous mef2A mRNA levels (Fig. 6B) . Furthermore an important downregulation was observed when expression of Rab5WT was performed in the presence of MEK5AA and was almost recovered in the presence of MEK5DD (Fig. 6A) . Taken together, these results suggested that HCVne particles are capable of activating the MEK5-ERK5-mef2 pathway when endocytosed in cells of hepatic origin.
ERK5 localization
The mechanisms that govern the subcellular distribution of ERK5 are largely unknown and various apparent discrepancies exist probably due to cell type. The C-terminal region of the ERK5 protein contains an active NLS (nuclear localization signal) and a NES (nuclear export signal), transforming the protein into a 'moving' cytoplasmicnuclear protein [35] . Therefore, several reports indicated that analogously to ERK 1/2 , ERK5 is a cytoplasmic protein that moves to the nucleus upon growth factor stimulation [33, 36] . However, other data have indicated that ERK5 may reside in the nucleus of HeLa or Rat-1, independently on their stimulation with growth factors [37] .
Huh7 starved cells were treated with HCVne for 30 min. Fluorescence confocal microscopy visualization revealed a cytoplasmic localization of endogenous ERK5 in resting cells that relocates to the nucleus after stimulation with EGF (Fig. 7A, B) supporting previous data for translocation of ERK5 to the nucleus after activation. In contrast, incubation with HCVne produced a perinuclear and in a few cases a nuclear distribution of ERK5 (Fig. 7C ).
Discussion
Mitogen-activated protein kinases (MAPKs) are highly conserved molecules that transduce extracellular stimuli into intracellular responses in different organisms [38, 39] . While other MAPK members are well characterized, ERK5 constitutes a relatively new kinase (discovered in 1995) that has not been fully investigated [12, [38] [39] [40] [41] . The physiological function of ERK5 signaling is just beginning to be elucidated. Growth factor activation of ERK5 in nonneuronal cells has been implicated in fibroblast cell proliferation, muscle cell differentiation, and cancer cell transformation [21, [42] [43] [44] . Different stimuli have been proposed to activate this pathway such as EGF (epidermal growth factor), TGFb (transforming growth factor-b), NGF (nerve growth factor) and PDGF (platelet-derived growth factor) as well as different oxidants and hyperosmolarity [12] . Furthermore, this pathway has been found to be activated in different type of cancers, including hepatocellular carcinoma, a state which is often observed in HCV chronic patients [4, 12, 45] . To our knowledge this is the first report describing involvement of hepatitis C virus proteins in the activation of ERK5 pathway. HCV core structural and NS5A non structural proteins are known to influence a great number of MAPK pathways [46] [47] [48] [49] , therefore, they were initially chosen in this study in order to investigate if their expression can provoke a potential induction of ERK5 phosphorylation. A range of assays was used, no activation of the pathway was observed upon exposure of cells to either of these proteins. In contrast, when cells of hepatic origin were challenged with HCV nonenveloped particles (HCVne), a significant phosphorylation of ERK5 protein was observed, with maximum activation after 30 min of incubation at 37°C. The signal was absent when heat-denatured HCVne particles or a control fraction of the same density was used in cells over the same time scale. This effect was shown to be specific as the increase in HCVne particles quantity was followed by an amplified signal. Furthermore, the particulate conformation seems to be important as no activation was observed when soluble core protein was used even at high concentrations.
It has been suggested that MEK5 protein acts as the major ERK5-activating kinase, with MEKK3 being an upstream activating kinase for MEK5 [41, 50] . The catalytic domains of MEK5 and MEK1 (member of the ERK 1/2 pathway) show a 46% amino acid sequence identity, making the use of MEK 1/2 inhibitors possible, as no specific inhibitors of the MEK5-ERK5 pathway exist [28] . Thus, to investigate the involvement of MEK5 protein in HCVne-ERK5 pathway activation, MEK 1/2 inhibitors UO126 and PD98059 were used. Furthermore, lower concentration of these inhibitors, generally used to block ERK 1/2 pathway, had no effect in ERK5 pathway. This result provides evidence that the observed ERK5 activation is not an effect of a cross-talk between ERK 1/2 and ERK5 pathways as it has been previously proposed [51] , but rather a direct ERK5 activation. However, the use of UO126 inhibitor at high concentration with an increased pretreatment time, efficiently blocked ERK5 phosphorylation, providing evidence of the involvement of MEK5 in the HCVne-ERK5 pathway activation. It is important to note that the use of PD98059 at high concentrations failed to inhibit the activation of the pathway. This phenomenon has already been described [52] and is probably due to a different mode of action of these inhibitors.
In addition HCVne particles were shown to activate a well known downstream target of the ERK5 pathway, mef2. MEF2 proteins belong to the MADS box (maintenance agamous deficient serum-response factor) transcription regulators family, with established roles in skeletal-cardiac smooth muscle differentiation and neuronal survival, as well as in gene regulation in response to mitogenic signaling and hepatocellular carcinoma [53] [54] [55] [56] . Furthermore, a relation of MEF2 protein with class II histone deacetylases (II HDACs) and histone acetyl transferases (HATs) has been characterized [57] . Altered histone acetylation is considered to influence regulation of gene transcription and eventually carcinogenesis. It is tempting to speculate that HCVne particles could influence this type of gene deregulation via MEF2 protein.
However, the mef2 gene has also been proposed to be regulated by the p38-MAPK pathway [58, 59] . The use of SB202190, a known p38 pathway inhibitor, in mef2-luc transfected cells was impossible in our experimental conditions due to the high toxicity effects of this agent (data not shown). Nevertheless, the activation observed by HCVne particles was completely abolished when high concentrations of UO126 inhibitor or overexpression of MEK5AA plasmid were used, proving no p38 involvement and a direct activation of the MEK5-ERK5-mef2 pathway. Although an extensive analysis of the link between ERK5 activation and the mechanism of endocytosis is needed, data obtained in this study by using the Rab5S34N mutant combined with the observation that the particulate form of core protein induces pathway activation, provide strong evidence that this activation was sensitized by HCVne endocytosis. It is noteworthy that HCV core in hepatocytes is capable of shifting TGF-b responses from cytostatic effects to EMT development [60] and ERK5 is considered to be a new component of hepatocyte response to TGFb [34] . Furthermore extracellular HIV tat protein was previously demonstrated to induce the production of high levels of TGF-b [61] suggesting that HCVne particles can act in a similar way.
It has been proposed that ERK5 can shuttle between the cytoplasm and the nucleus depending on the stimulation [37, 62] . Although we have observed some nuclear translocation of ERK5 after HCVne incubation, supporting direct mef2 activation, we cannot exclude the possibility for an indirect activation of this transcription factor. As an example it was recently reported that calcium is required for EGF-induced ERK5 activation [63] and a possible alteration of intracellular calcium levels after HCVne endocytosis cannot be excluded, as well as influences causing induction of cellular stresses such as H 2 O 2 and fluid shear stress [64, 65] .
In conclusion, data presented in this study provide evidence that HCVne particles can specifically activate the MEK5-ERK5-mef2 pathway as summarized in Fig. 8 . HCV nucleocapsids can be found in significant quantities in serum. HCV propagation although progressed, is restricted to certain genotypes and moreover HCV production of different forms of viral particles in cell culture is still largely limited, begging the question of whether naturally occurring HCVne particles can indeed be potent regulators of critical signaling pathways. Additional information is required in order to clarify this mechanism and to resolve the intriguing puzzle concerning the role of HCVne particles as modulators of MAPK signaling. [9] . By 30 min the MEK5-ERK5 pathway is induced, followed by mef2 activation.
